肾上腺皮质功能减退症 中国就医指南

Adrenocortical insufficiency (AI) is a potentially life-threatening endocrine disorder characterized by inadequate production of adrenal corticosteroids—primarily cortisol and, in some cases, aldosterone—by the adrenal cortex. It is classified into primary (Addison’s disease), secondary (due to pituitary ACTH deficiency), and tertiary (due to hypothalamic CRH deficiency) forms. Primary AI results from direct adrenal gland damage—most commonly autoimmune adrenalitis (accounting for ~80% of cases in high-income countries), but also infections (e.g., tuberculosis, HIV-associated mycobacterial or fungal infections), bilateral adrenal hemorrhage, metastatic malignancy, or genetic disorders (e.g., congenital adrenal hyperplasia, adrenoleukodystrophy). Secondary and tertiary AI arise from impaired stimulation of the adrenal glands due to pituitary or hypothalamic dysfunction, often triggered by prolonged exogenous glucocorticoid therapy, pituitary tumors, surgery, radiation, or infiltrative diseases. Epidemiologically, primary AI affects approximately 100–140 per million people globally, with an annual incidence of 4–6 per million; it occurs equally across sexes and peaks in the 30–50 age range. Secondary AI is significantly more common—especially among patients with chronic glucocorticoid use—and its true prevalence is likely underreported. Key risk factors include prior autoimmune conditions (e.g., type 1 diabetes, thyroiditis, vitiligo), long-term systemic corticosteroid treatment (>3 weeks at ≥5 mg prednisone equivalent/day), pituitary/hypothalamic pathology, critical illness with adrenal involvement, and genetic predisposition (e.g., AIRE gene mutations in APS-1). Untreated or poorly managed AI profoundly impairs quality of life: patients frequently experience debilitating fatigue, orthostatic dizziness, unintentional weight loss, gastrointestinal distress (nausea, vomiting, abdominal pain), salt craving, hypoglycemia, depression, brain fog, and reduced physical stamina. Acute adrenal crisis—a medical emergency marked by hypotension, shock, hyponatremia, hyperkalemia, and altered mental status—carries a mortality rate of 6–25% if not promptly treated. Even in stable chronic management, patients report limitations in work capacity, social engagement, and emotional resilience due to fear of crisis, medication adherence burden, and unpredictable symptom flares during stressors (e.g., infection, injury, surgery). Lifelong hormone replacement (glucocorticoids ± mineralocorticoids), patient education on sick-day rules, and regular endocrinology follow-up are essential to mitigate morbidity and restore functional well-being.

# 肾上腺皮质功能减退症治疗方案与费用明细（内分泌科）

一、非手术/保守治疗（一线方案）

适用人群：原发性（如Addison病）、继发性（垂体功能减退）及医源性患者，无急性肾上腺危象。

• •基础替代治疗：氢化可的松（生理剂量）+氟氢可的松（盐皮质激素）

• •必要检查：血皮质醇、ACTH、电解质、肾素-醛固酮、24h尿游离皮质醇

二、急性肾上腺危象抢救（急诊干预）

适用人群：发热、呕吐、低血压、意识障碍等危象状态。

• •静脉氢化可的松冲击（100mg iv bolus + 200mg/24h维持）+补液纠电解质

三、病因特异性干预（非根治性）

• •垂体瘤致继发性减退：转神经外科评估是否需经蝶手术（见下）
• •自身免疫性多腺体综合征：同步甲状腺/性腺功能评估与替代（额外检验费¥600–¥1,200）

四、手术/介入方案（仅限病因治疗）

适用条件：明确由垂体大腺瘤、肾上腺结核钙化灶压迫或罕见肾上腺转移瘤所致者。

• •经蝶垂体瘤切除术（神经外科协作）：¥32,000–¥58,000（含术前垂体MRI ¥800–¥1,200）
• •肾上腺活检/消融（极少数诊断不明者）：¥18,000–¥26,000

五、特殊复杂情况

• •耐药性低醛固酮血症：加用去氧皮质酮（DOC）注射剂，¥2,400–¥4,800/月
• •合并严重感染/心衰：需个体化糖皮质激素增量+多学科会诊，单次MDT费用¥1,200

方案快速选择指南

✅ 稳定慢性期：首选口服替代治疗（¥120–¥380/月）+年度复查（¥1,500） ✅ 突发危象：立即急诊静脉替代（¥8,500起） ✅ 垂体结构性病变：转诊神经外科评估手术（¥32,000起） ⚠️ 切勿自行停药/减量——所有方案须在内分泌科医师全程随访下调整